Raltitrexed
| File:Raltitrexed.svg | |
| Raltitrexed
| |
| Systematic (IUPAC) name | |
| 2-[5-[methyl- [(2-methyl-4-oxo-1H- quinazolin-6-yl)methyl] amino] thiophen-2- yl] carbonylaminopentanedioic acid | |
| Identifiers | |
| CAS number | |
| ATC code | L01 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C21H22N4O6S |
| Mol. mass | 458.489 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
|
WikiDoc Resources for Raltitrexed | |
|
Articles | |
|---|---|
|
Most recent articles on Raltitrexed Most cited articles on Raltitrexed | |
|
Media | |
|
Powerpoint slides on Raltitrexed | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Raltitrexed at Clinical Trials.gov Clinical Trials on Raltitrexed at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Raltitrexed
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Raltitrexed Discussion groups on Raltitrexed Patient Handouts on Raltitrexed Directions to Hospitals Treating Raltitrexed Risk calculators and risk factors for Raltitrexed
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Raltitrexed | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Business | |
|
Experimental / Informatics | |
Overview
Raltitrexed (brand name Tomudex®) is a chemotherapy drug manufactured AstraZeneca Company, is an antimetabolite used in chemotherapy. It is an inhibitor of thymidylate synthase.
Uses
Used in treatment of colorectal cancer since 1998.
Mechanism of action
Raltitrexed is chemically similar to folic acid and is in the class of chemotherapy drugs called folate antimetabolites. It works by inhibiting enzyme used in pyrimidine synthesis —thymidylate synthase (TS). Raltitrexed is fully active after polyglutamylation. Inhibition of L1210 cell growth i culture IC50 = 9 nM, is one of the strongest antimetabolite in use. By inhibiting the formation of precursor pyrimidine nucleotides, raltitrexed prevents the formation of DNA and RNA, which are required for the growth and survival of both normal cells and cancer cells.
Table of Contents In Alphabetical Order | By Individual Diseases | Signs and Symptoms | Physical Examination | Lab Tests | Drugs
Editor Tools Become an Editor | Editors Help Menu | Create a Page | Edit a Page | Upload a Picture or File | Printable version | Permanent link | Maintain Pages | What Pages Link HereThere is no pharmaceutical or device industry support for this site and we need your viewer supported Donations | Editorial Board | Governance | Licensing | Disclaimers | Avoid Plagiarism | Policies